Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18938843 | 0.87 | MCL1 (0.37) | MCL1KMT2AMEN1 | |
| SCHEMBL13446697 | 0.87 | MCL1 (0.37) | MCL1KMT2AMEN1 | |
| SCHEMBL13446632 | 0.82 | MCL1 (0.39) | MCL1KMT2AMEN1 | |
| SCHEMBL4911744 | 0.80 | KMT2A (0.34) | KMT2AMIFCYP2C19 | |
| SCHEMBL14582197 | 0.79 | MCL1 (0.36) | MCL1KMT2AMEN1 | |
| SCHEMBL10900754 | 0.78 | HTT (0.45) | MCL1CYP2C19 | |
| SCHEMBL13446683 | 0.77 | MCL1 (0.34) | MCL1 | |
| SCHEMBL13411806 | 0.76 | MEN1 (0.31) | KMT2AMEN1 | |
| SCHEMBL27496508 | 0.76 | MCL1 (0.46) | MCL1KMT2AMEN1 | |
| SCHEMBL15709925 | 0.75 | MCL1 (0.33) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633415-B2 | Compounds and methods useful for treating or preventing cancers | THE BROAD INSTITUTE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220096513-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2018183936-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-5446194-A | Pharmacologically active catechol derivatives | ORION-YHTYMA OY (FI) | 1995-08-29 | — | — | US | disclosed |
| US-5386047-A | Monomers for heat resistant, high bonding strength cyanoacrylate adhesives | LOCTITE CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0470722-B1 | Novel alpha-cyanoacrylate and adhesive composition | THREE BOND CO LTD (JP) | 1994-03-02 | — | — | EP | disclosed |
| US-5290838-A | Nonwhitening cyanoacrylate copolymers | THREE BOND CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| US-5283352-A | Transferase inhibitor | ORION-YHTYMA OY (FI) | 1994-02-01 | — | — | US | disclosed |
| US-5175337-A | Heat resistant adhesives for quick strong bonds | THREE BOND CO., LTD. (JP) | 1992-12-29 | — | — | US | disclosed |
| US-5112861-A | Inhibitors of catechol-methyl-transferase enzyme, levodopa | ORION-YHTYMA OY (FI) | 1992-05-12 | — | — | US | disclosed |
| EP-0470722-A1 | Novel alpha-cyanoacrylate and adhesive composition | THREE BOND CO., LTD. (JP) | 1992-02-12 | — | — | EP | disclosed |
| US-4963590-A | ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION | ORION-YHTYMA OY (FI) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096513-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | CSNK1A1, CSNK2A1, CSNK2A3 | MCL1 4/4885KMT2A 74/4885MEN1 1939/4885 |
| US-11633415-B2 | Compounds and methods useful for treating or preventing cancers | CSNK1A1, CSNK2A1, CSNK2A3 | MCL1 4/4885KMT2A 74/4885MEN1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.